Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 6Urinary Bladder Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Smoking Cessation 1Prostatic Hyperplasia 1Precancerous Conditions 1Papillomavirus Infections 1Non-melanomatous Skin Cancer 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Condylomata Acuminata 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Barrett Esophagus 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × polyphenon E × Clear all
NCT00088946 2020-07-31

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Completed
17 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00666562 2017-11-17

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡